Boston, United States
Solu Therapeutics, founded in 2022, is carving a niche in the Biotechnology and Health and Wellness sectors. Headquartered in the United States, the company asserts its mission with the slogan: "Solu Therapeutics is a next-generation therapeutics focused company working to eliminate cells that drive diseases."
As a precision-medicine entity, Solu Therapeutics is committed to developing groundbreaking therapeutics targeting cells central to oncologic, inflammatory, and autoimmune diseases. This innovative focus offers significant potential in addressing complex health issues that are currently underserved.
Recently, the company secured a $31.00M Seed Round investment on 01 August 2023, indicative of strong confidence by prominent investors such as Longwood Fund, Santé Ventures, Alexandria Venture Investments, Astellas Venture Management, and DCVC Bio. This financial backing positions Solu Therapeutics well for future advancements and scaling.
